Lupin Launches Glucagon for Injection in U.S., Reports Strong Q1 FY2026 Results
Lupin Limited has launched Glucagon for Injection USP in the United States, a product with estimated annual sales of $122 million. The company also reported robust Q1 FY2026 results, with revenue up 11.8% to INR 6,164 crores and EBITDA increasing 27.6% to INR 1,641 crores. U.S. business grew 22.3%, driven by Tolvaptan launch. India business expanded 7.8%, outperforming in key therapeutic areas. The company expects strong double-digit growth for FY2026 with 24-25% EBITDA margin guidance, despite potential competitive pressures.
*this image is generated using AI for illustrative purposes only.
Lupin Limited , a global pharmaceutical leader, has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States. This launch comes on the heels of the company reporting robust financial results for the first quarter of fiscal year 2026, marking a strong start to the year.
Glucagon Launch in the U.S.
Lupin's Glucagon for Injection USP is bioequivalent to Eli Lilly and Company's Glucagon for Injection. The product is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. It also serves as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adult patients.
The launch of Glucagon for Injection USP represents a significant opportunity for Lupin, with the product having an estimated annual sale of USD 122.00 million in the U.S. market, according to IQVIA MAT June 2025 data.
Strong Q1 FY2026 Performance
Lupin reported impressive financial results for Q1 FY2026:
- Revenue reached INR 6,164.00 crores, up 11.8% year-over-year
- EBITDA increased by 27.6% to INR 1,641.00 crores
- EBITDA margins improved to 26.6%, up 330 basis points from the previous year
Key Business Highlights
U.S. Business Growth
The U.S. business recorded sales of USD 282.00 million, growing 22.3% year-over-year. This growth was primarily driven by the successful launch of Tolvaptan with sole first-to-file exclusivity.
India Business Performance
The India region business grew by 7.8% year-over-year, with the prescription business expanding by 8.6%. Key therapeutic areas like Cardiovascular, Gastrointestinal, and Vitamins, Minerals, and Supplements (VMS) outperformed the Indian Pharmaceutical Market (IPM) growth.
Other Markets
Other Developed Markets, including Europe, saw a 17% year-over-year increase in revenues, with Europe alone growing by 28%. The Global Institution Business (GIB) also showed strong performance, growing by 16% year-over-year.
Strategic Developments and Future Outlook
Lupin has made significant strides in expanding its complex generics portfolio, particularly in injectables, respiratory products, and biosimilars. The company received FDA approvals for generic Victoza and Glucagon, with Glucagon already launched and Liraglutide planned for October launch.
The management expects strong double-digit growth for FY2026, with EBITDA margin guidance of 24-25%. However, the company faces competitive pressures from new generic competition in Albuterol and potential additional competition for Tolvaptan.
Vinita Gupta, CEO of Lupin Limited, expressed optimism about the company's growth prospects, stating, "We are very optimistic that we continue our growth momentum this fiscal year as well as in the next couple of years despite the challenges on additional competition on key products. We believe that we have significant growth drivers in place."
As Lupin continues to focus on complex generics and specialty products, with nearly 70% of its R&D investments directed towards these areas, the company appears well-positioned for sustained growth in the coming years.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.42% | +0.89% | +1.84% | -0.42% | -5.42% | +92.65% |
18
